Blogs
E Market Briefing For Thursday, February 20
Article By:
Gene Inger
Read
Thursday, February 20, 2020 3:54 AM EST
Persistent 'top-heavy' dominance - of the S&P continues churning-out higher highs, irrespective of growth downgrades anticipated, while some other stocks, with actual growth potential, languish relatively.
Healthcare (Top 30 Weights) Earnings Estimates And Revisions
Article By:
T.J. Hayes
Read
Monday, February 17, 2020 5:44 AM EST
The cumulative 2020 earnings power of these 30 stocks was revised down by -.34% in the past 60 days.
In this article: EW, HCA, HUM, JNJ, LLY, MDT, MRK, PFE, SYK, TMO, UNH, ILMN, AMGN, BIIB, GILD, ISRG, VRTX Also: ABT, AGN, BAX, BDX, BMY, BSX, CI, CNC, CVS, DHR, XLV, ZTS, ABBV, ANTM
Paulson Adds Pretium, Exits United Tech In Q4
Article By:
The Fly
Read
Sunday, February 16, 2020 12:29 PM EST
John Paulson's Paulson & Co. disclosed in an SEC filing its holdings as of December 31, 2019. The fund's top holdings as of December 31, in order of size, were Bausch Health, SPDR Gold Shares, Allergan, Discovery Class C and Horizon Therapeutics
In this article: AGN, CPE, PCG, QEP, S, TIF, UTX, LOGM, DISCK, GOLD, HZNP, TECD, GLD, PVG, CZR, BHC, NMRK, INSW, LYFT
Alkermes Targets Bipolar Disorder And Schizophrenia
Article By:
MoneyShow.com
Read
Sunday, February 16, 2020 11:52 AM EST
We strongly recommend that investors take advantage of the weakness and buy Alkermes, whose treatment of schizophrenia and bipolar disorder has been accepted by the FDA for review.
Week In Review: Bio-Thera Raises $241 Million In Shanghai STAR IPO For Antibody Portfolio
Article By:
ChinaBio® Today
Read
Saturday, February 15, 2020 4:19 PM EST
Bio-Thera Solutions of Guangzhou priced its IPO on Shanghai’s STAR Board to raise $241 million at a valuation of almost $2 billion. The offering, which placed 60 million shares at RMB32.76 each, was reported to be 3,225 times oversubscribed.
Aptose Biosciences - Chart Of The Day
Article By:
Jim Van Meerten
Read
Friday, February 14, 2020 2:43 PM EST
Aptose Biosciences Inc. is a clinical-stage biotechnology company.
E Canopy Growth Reports Very Positive Q3 Results - Stock Jumps
Article By:
Lorimer Wilson
Read
Friday, February 14, 2020 12:35 PM EST
Canopy Growth Corporation today announced its financial results for the third quarter ended December 31, 2019, and stock jumps.
E Aurora Cannabis Q2 2020 Results Show Declines Across The Board
Article By:
Lorimer Wilson
Read
Thursday, February 13, 2020 7:00 AM EST
Aurora reiterates its outlook for Q3 that cannabis revenue will be impacted by industry headwinds, and as such will likely show modest to no growth relative to fiscal Q2's cannabis revenue.
In this article: ACB
E Inovio Pharmaceuticals: 2020 Is The Make Or Break Year
Article By:
Sunil Tinani
Read
Monday, February 10, 2020 10:52 AM EST
Inovio Pharmaceuticals has been a non-performer on the charts as it has yet to breakthrough the markets, and because of its rich valuations. However, 2020 offers hope and can prove to be a turnaround year.
Biotech Stock Segment Going Bananas In February 2020
Article By:
Taki Tsaklanos
Read
Sunday, February 9, 2020 2:37 PM EST
One sector that is going crazy is the biotech stock sector. One thing we do know about markets that go bananas: if it’s unclear what their intention is you better stay at the sidelines.
In this article: IBB